EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
Joined: Feb 19, 2006 Posts: 358 Location: suburb of Chicago, IL USA
Posted: Mon Oct 02, 2006 5:43 pm Post subject: Copaxone at ECTRIMS
Glatiramer Acetate Shows Positive Impact on Average Relapse Rate and Disease Progression in Multiple Sclerosis For Up to 5 Years: Presented at ECTRIMS
By Bruce Sylvester
MADRID, SPAIN -- October 1, 2006 -- Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
The findings were presented here on September 28th at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
"Glatiramer treatment not only has a positive impact on relapse rate and disease progression but we found that the effect increases over time, out to 5 years," said lead presenter Paul Hradilek, MD, neurologist, University Hospital, Ostrova, Czech Republic. "The drug is very effective on both fronts in relapsing-remitting MS patients."
The study cohort consisted of 96 women and 12 men diagnosed with relapsing-remitting multiple sclerosis who began glatiramer treatment in1999. For 95 patients glatiramer was their first disease-modifying drug. Thirteen had been treated previously with interferons.
For study entry, participants were required to have at least 2 relapses per year or 3 relapses every 2 years and magnetic resonance imaging finding confirming an MS diagnosis.
Average time from diagnosis to initiation of treatment with glatiramer was 6.75 years (1-30).
Investigators evaluated relapse rate and Expanded Disability Status Scale (EDSS) change in subgroups treated at least 1, 3 or 5 years.
Average relapse rate before treatment was 1.5. After 1 year of glatiramer treatment the rate decreased to 0.68. With glatiramer treatment, it continued to decrease after 3 years to 0.51. In the subgroup treated for at least 5 years the relapse rate was 0.31.
A majority of subjects showed stable EDSS scores, with an average change in EDSS of 0.1 point after 5 years.
The authors noted that 5 patients discontinued treatment. There were 2 skin allergic reactions leading to discontinuation, but no other major side effects.
Eleven patients became pregnant during glatiramer treatment, "which was interrupted the day the subjects knew about their pregnancy," Dr. Hradilek said. There were 3 spontaneous abortions and 8 normal deliveries. The researcher did not observe any foetal abnormalities.
Copaxone is approved in much of the world for relapsing-remitting MS. It acts as both immunomodulatory and neuroprotective agent.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project.
Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS,
on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
